The patient pathway
The patient pathway. This is a pillar page: orient the reader, compare the main choices, and route into its four focused guides. Editorial contract: Describe th
Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act 1975, not a general licence to use cannabis. Since the Medicinal Cannabis Scheme came into effect in April 2020, the Ministry of Health has overseen a framework where products must meet Good Manufacturing Practice (GMP) standards and be approved by Medsafe before they can be prescribed. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated products. The legal product is a manufactured pharmaceutical, and the raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.
This page is the overview of that pathway. It is not a clinical guide, a product review, or a promise of access. It describes the regulated route from a doctor’s consultation to a pharmacy-dispensed product, and it points to four focused guides where you can go deeper.
What is medicinal cannabis in New Zealand?
Medicinal cannabis is a prescription medicine in New Zealand. It is not a general licence to use cannabis, and it is not the same as the raw plant material people may associate with recreational use. Under the Misuse of Drugs Act 1975, the Medicinal Cannabis Scheme (established by the Misuse of Drugs (Medicinal Cannabis) Regulations 2019) legalises access to cannabis-based products when a medical practitioner prescribes them. The scheme is administered by the Medicinal Cannabis Agency (MCA), which sits within Medsafe, New Zealand’s medicines regulator (Medsafe, 2020).
The key boundary: a prescription from a doctor is required. The scheme does not create a “green light” for general use. Products must meet Good Manufacturing Practice (GMP) standards and be approved by the Ministry of Health. This means the legal product is a manufactured pharmaceutical, not raw plant material bought from an unregulated source. Even the raw flower, when prescribed, is dispensed through a pharmacy, not a dispensary.
What the scheme does not do: It does not legalise recreational use, it does not allow self-medication with street cannabis, and it does not permit a doctor to write a prescription for a product that has not been approved under the scheme. The Misuse of Drugs Act remains the legal boundary, and the Medicinal Cannabis Scheme (established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019) is the only lawful route to access.
Medicinal cannabis in New Zealand
Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway, not a general licence to use cannabis. Under the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, a medical practitioner can prescribe a cannabis-based product for a patient, and the product must meet GMP standards and be approved by the Ministry of Health. The Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency within Medsafe, sets the quality, labelling, and manufacturing rules.
The key legal point: “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material bought from an unregulated source. The legal product is a manufactured pharmaceutical. Even the dried flower, when prescribed, is dispensed through a pharmacy, not a dispensary, and the patient must follow the prescription exactly. There is no general licence to possess or use cannabis for medical purposes outside this pathway. The Misuse of Drugs Act 1975 still governs the possession and supply of cannabis; the Medicinal Cannabis Scheme (Misuse of Drugs (Medicinal Cannabis) Regulations 2019) provides the only legal route for patients, and it operates through a prescription from a medical practitioner. The scheme is administered by the Medicinal Cannabis Agency, a unit within Medsafe, the New Zealand regulator.
The patient pathway
What this page covers
If you are reading this, you are probably trying to make sense of how medicinal cannabis actually works in New Zealand. You may be a patient, a whānau member, a clinician, or someone researching the system. This page gives you the map. It explains the legal route, the main choices you will meet, and where to go next. It does not recommend any product, dose or prescriber.
The four focused guides in this section own the detail; this page owns the overview. After reading it, you will know how the New Zealand Medicinal Cannabis Scheme works, what a prescription involves, how CBD and THC differ, and what questions to take to a clinician.
What “medicinal cannabis” means in New Zealand
Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act, not a general licence to use cannabis. The Medicinal Cannabis Scheme, administered by the Ministry of Health, legalises access through a prescription from a medical practitioner. Products must meet Good Manufacturing Practice (GMP) standards and be approved by the Ministry of Health.
The common misunderstanding is that “legal medicinal cannabis” means a patient can legally smoke raw plant material or buy unregulated products. That is not the case. The legal product is a manufactured pharmaceutical. Raw flower is available, but it is prescribed and dispensed through a pharmacy, not a dispensary. The scheme does not create a general licence to possess or use cannabis; it creates a regulated pharmaceutical pathway under the Misuse of Drugs Act 1975. Products that are not part of this scheme remain illegal, regardless of how they are marketed.
This page is your entry point to that pathway. It explains what medicinal cannabis is in New Zealand, how the prescription process works, the difference between CBD and THC, and where to go next.
What medicinal cannabis is (and is not) in New Zealand
Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway, not a general licence to use cannabis. Under the Misuse of Drugs Act 1975, cannabis remains a controlled drug, but the Medicinal Cannabis Scheme, established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, provides a legal route for patients to access quality-assured products through a prescription from a medical practitioner. The scheme is administered by the Medicinal Cannabis Agency (MCA), which sits within Medsafe, New Zealand’s medicines regulator. The Ministry of Health states that products must meet Good Manufacturing Practice (GMP) standards and be approved before they can be prescribed and dispensed.
The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated products. The legal product is a manufactured pharmaceutical. Raw flower is available, but it is prescribed and dispensed through a pharmacy, not a dispensary. The Misuse of Drugs Act 1975 (as amended by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018) sets the legal frame: a medical practitioner can prescribe, a pharmacist can dispense, and the patient can possess and use the product as directed. Possession outside that prescription remains illegal.
What is medicinal cannabis?
Medicinal cannabis is the term used in New Zealand for cannabis-based products prescribed by a medical practitioner under the Medicinal Cannabis Scheme. It is not a general licence to use cannabis, and it is not the same as “medical marijuana” sold overseas or in unregulated local outlets. Under the Misuse of Drugs Act, cannabis remains a controlled drug; the scheme creates a legal pathway for prescription access only.
The scheme, established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, legalises the cultivation, manufacture, supply, and possession of medicinal cannabis products that meet GMP (Good Manufacturing Practice) standards and are approved by the Ministry of Health. The products are manufactured pharmaceuticals, not raw plant material sold as a “natural” remedy. While dried flower is available, it is prescribed and dispensed through a pharmacy, not a dispensary. The Medicinal Cannabis Agency (MCA), part of Medsafe, administers the scheme.
The one question this page answers
What is the regulated patient pathway for medicinal cannabis in New Zealand, and what are the main choices and legal boundaries along it?
This page is the overview. It will not tell you which product is “best” or whether cannabis will help your condition; those decisions belong to your prescriber and to the focused guides. It will tell you how the pathway works, who is involved, and where to go next.
1. What counts as “medicinal cannabis” in New Zealand
Medicinal cannabis is not a single plant or product. Under the Misuse of Drugs Act 1977, it is a regulated pharmaceutical pathway. The Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 created the Medicinal Cannabis Scheme, which came into force on 1 April 2020. The scheme is administered by the Medicinal Cannabis Agency (MCA), a unit within Medsafe, New Zealand’s medicines regulator.
Under the scheme, a medical practitioner can prescribe a cannabis-based product for a patient. The product must meet good manufacturing practice (GMP) standards and be approved by the Ministry of Health. This is a significant point: “legal medicinal cannabis” in New Zealand does not mean a patient can legally smoke raw plant material bought from an unregulated source. The legal product is a manufactured pharmaceutical. Even when the product is dried flower, it is prescribed and dispensed through a pharmacy, not a dispensary.
The scheme operates under the Misuse of Drugs Act 1975, and the Ministry of Health’s Medicinal Cannabis Agency (MCA), part of Medsafe, administers it. The legal framework is the Medicinal Cannabis Scheme, established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which came into force on 1 April 2020. Since that date, a medical practitioner can prescribe medicinal cannabis products that meet GMP standards and have been notified to the Ministry of Health. The scheme does not legalise recreational use, nor does it allow smoking raw plant material outside a prescription.
Why this page exists
If you are reading this, you are likely trying to find out whether medicinal cannabis is an option for you or someone you care for. The legal framework in New Zealand is often confused with the general legalisation debate. This page is the overview: it maps the entire journey, from the first conversation with a clinician to the pharmacy counter, and points you to the four detailed guides that cover each stage in depth. It does not diagnose, prescribe, or promise access.
What medicinal cannabis is in New Zealand
Medicinal cannabis is a regulated pharmaceutical pathway under the Misuse of Drugs Act 1975. It is not a general licence to use cannabis. Under the Medicinal Cannabis Scheme, which is administered by the Ministry of Health and regulated by Medsafe, a medical practitioner can prescribe a manufactured cannabis product for a patient. Products must meet Good Manufacturing Practice (GMP) standards and be approved by the Ministry of Health. The scheme was established by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and came into force on 1 April 2020, according to the New Zealand Ministry of Health.
The most common misunderstanding is that “legal medicinal cannabis” means a patient can legally smoke raw plant material or buy unregulated products. In New Zealand, the legal product is a manufactured pharmaceutical. Even raw flower, when prescribed, is dispensed through a pharmacy and is subject to the same quality and labelling rules as other medicines. It is not sold through a dispensary or a wellness shop.
Read next
- Talking to a doctor about medicinal cannabis Talking to a doctor about medicinal cannabis. Prepare symptoms, treatments, goals, risks and questions. The page must give the reader a usable method, checklist
- What a prescriber considers What a prescriber considers. Cover evidence, interactions, contraindications, monitoring and alternatives. The page must give the reader a usable method, checkl
- Prescription and pharmacy process Prescription and pharmacy process. Explain roles, supply and why timing varies. The page must give the reader a usable method, checklist or decision rule, not a
- Review and monitoring Review and monitoring. Track benefit, function and adverse effects with a clinician. The page must give the reader a usable method, checklist or decision rule,
- Understanding the evidence Understanding the evidence. This is a pillar page: orient the reader, compare the main choices, and route into its four focused guides. Editorial contract: Name